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Clinics and pathology 
Disease 
ANLL; t-ANLL 
Phenotype / cell stem origin 
M4, M5a, M5b; possible involvement of a granulo-
monocytic precursor; no preceeding MDS. 
Epidemiology 
Rare disease (<1% of ANLL); found in children 
(including infants) and young adults of both sexes. 
Clinics 
Disseminated intra vascular coagulation may be 
present; extramedullary infiltration; 20% of the cases 
could be therapy-related. 
Cytology 
Erythrophagocytosis, strong peroxidase and esterase 
activities. 
Prognosis 
Poor: remission may be obtained in half cases; 
infections, bleeding; survival is often less than 1 year. 
Cytogenetics 
Additional anomalies 
In half cases; +8, various; complex karyotype may be 
found. 
Variants 
Complex t(8;16;Var) involving a (variable) third 
chromosome have been described; 8p11 breakpoint 
with another partner as well, of which is the recurrent 
t(8;22)(p11;q13), which may involve P300 on 22q13 in 
the place of CBP: this translocation would therefor be 
an equivalent (not identical), and not a simple variant 
with hidden 16p13 involvement. 
 









5’ MOZ - 3’ CBP 
Fusion protein 
Description 
N-term MOZ fused to most of CBP; 3722 amino acids; 
415 kDa; combines the MOZ finger motifs (DNA 
binding) and acetyl transferase with the transcriptional 
coactivator from CBP; the reciprocal CBP-MOZ has no 
role (as it is out of frame). 
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